Georgia Chapter 2019 Annual Meeting

Atlanta, GA US
February 8, 2019 to February 9, 2019

The Georgia Chapter of AACE Annual Meeting is designed to provide a forum devoted exclusively to endocrinology at which leaders in the field present recent clinical updates and other relevant clinical information.

Target Audience

Endocrinologists, MD/DOs, advance practice clinicians, and other interested healthcare professionals who are interested in the treatment of endocrine disease states that reside or practice in the state of Georgia.

Learning Objectives

  • Discuss the latest scientific and clinical discoveries in the field of endocrinology and diabetes.

  • Apply new found knowledge to the diagnosis and management of patients with disorders of endocrinology, diabetes or metabolism for improved patient outcomes.

  • Establish new collaborations and relationships with peers for improved personal and professional support.

Additional information
AttachmentSize
2019 Georgia Annual Meeting714.58 KB
Available for MOC Points?: 
No
Practice Area: 
Endo Surgery
Course summary
Available credit: 
  • 8.00 AMA
  • 8.00 Attendance
Course opens: 
02/08/2019
Course expires: 
12/31/2019
Event starts: 
02/08/2019 - 1:00pm
Event ends: 
02/09/2019 - 5:00pm
Cost:
$0.00

Agenda

Friday, February 8, 2019

1:00 – 1:30 p.m.               Registration Open & Break

1:30 – 1:45 p.m.               Welcome Remarks & Pre-Session Assessment

Objectives: After participating in a pre-meeting assessment tool, attendees will be able to recognize areas of potential shortcoming and strive to improve knowledge and consequential healthcare practices.

1:45 – 2:30 p.m.               Endocrinopathies Secondary to Immune Check Point Inhibitors

                                         Roberto Salvatori, MD

Objectives: At the end of this session, participants will be able to:

  • Discuss the mechanism of immune check point inhibitors endocrinopathies.
  • Identify the signs and symptoms of these endocrinopathies.
  • Discuss appropriate treatment of immune checkpoint inhibitor endocrinopathies.

2:30 – 3:15 p.m.               Preventing Diabetes vs. Treating Prediabetes

                                         Leigh Perreault, MD

Objectives: At the end of this session, participants will be able to:

  • Review the studies preventing type 2 diabetes in people with prediabetes.
  • Discuss the guidelines for treatment vs prevention in people with prediabetes.
  • Explore the rationale for treating people with prediabetes to prevent diabetes-related complications.

              

3:15 – 3:45 p.m.               Break

3:45 – 4:30 p.m.               Modern Treatment of Type 2 Diabetes: Incorporating the latest evidence and guidelines into practice

                                         Richard Pratley, MD

Objectives: At the end of this session, participants will be able to:

  • Discuss the results of recent cardiovascular outcomes studies in patients with type 2 diabetes mellitus.
  • Compare various diabetes treatments and discuss whether they adequately address comorbid cardiovascular events.
  • Assess the new ADA/EASD recommendations for managing patients with type 2 diabetes mellitus and how this affects your practice.

4:30 – 5:15 p.m.               Diabetes / Obesity Panel

                                         Leigh Perreault, MD; Richard Pratley, MD; Margaret Presswood, MS, NP-C

5:15 – 5:30 p.m.               Post-Session Assessment

Objectives:

At the conclusion of the meeting, attendees will be able to measure learning that occurred that will enable the use of new healthcare techniques and practices and to review or confirm existing care modalities.

5:30 – 6:15 p.m.               Reception

Saturday, February 9, 2019

8:00 – 8:45 a.m.                              Registration / Continental Breakfast

8:45 – 9:00 a.m.                              Welcome Remarks & Pre-Session Assessment

Objectives:

After participating in a pre-meeting assessment tool, attendees will be able to recognize areas of potential shortcoming and strive to improve knowledge and consequential healthcare practices.

9:00 – 9:45 a.m.               Male Hypogonadism:  Is treatment still controversial?

                                         Mark Molitch, MD

Objectives: At the end of this session, participants will be able to:

  • List 3 potential benefits of testosterone treatment of hypogonadal men.
  • List at least 3 ways of providing testosterone replacement.
  • Discuss fertility aspects of hypogonadal men.

9:45 – 10:30 a.m.             Uncommon Bone Diseases

                                         Pauline Camacho, MD, FACE

Objectives: At the end of this session, participants will be able to:

  • Discuss the clinical presentation and treatment of Paget's disease.
  • Discuss the clinical presentation and treatment of osteogenesis imperfecta.
  • Discuss the clinical presentation and treatment of hypophosphatasia, specifically the adult form.

10:30 – 11:00 a.m.          Break

11:00 – 11:45 a.m.          Challenges in the Management of Hyperprolactinemia

                                       Sue Samson, MD, PhD, FRCPC, FACE

Objectives: At the end of this session, participants will be able to:

  • Discuss the approach to the management of prolactinomas that appear to be resistant to conventional dopamine agonist dosing.
  • Describe possible mechanisms for prolactinoma resistance or apparent resistance.
  • Explain the surgical options that exist for select prolactinoma patients when medial options are less than ideal.

11:45 – 12:15 p.m.          GA-AACE Business Meeting

12:30 – 1:30 p.m.            Lunch

1:45 – 2:30 p.m.               Managing Graves’ Hyperthyroidism

                                        Doug Ross, MD

Objectives: At the end of this session, participants will be able to:

  • Employ new paradigms for determining the etiology of thyrotoxicosis.
  • Discuss the three treatment options for hyperthyroidism with patients, including the long-term use of anti-thyroid drugs.
  • Discuss the difficult choices for women with Graves’ disease desiring pregnancy.

2:30 – 3:30 p.m.               Thyroid Surgery 2019: Disasters, near-misses, and home-runs

                                         Amy Chen, MD, MPH, FACS, FACE; Dave Terris, MD, FACS, FACE

Objectives: At the end of this session, participants will be able to:

  • Discuss many of the common challenges faced in modern thyroid surgery.
  • Appreciate the importance of thorough preoperative preparation prior to undertaking management of thyroid diseases, and especially cancer.
  • Recognize factors associated with excellent outcomes in both primary and re-operative thyroid surgery.

3:30 – 3:45 p.m.               Post Session Assessment

Objectives:

At the conclusion of the meeting, attendees will be able to measure learning that occurred that will enable the use of new healthcare techniques and practices and to review or confirm existing care modalities.

3:45 p.m.                           Closing Remarks & Adjourn

W Atlanta Downtown Hotel
45 Ivan Allen Jr Blvd NW
Atlanta, GA 30308
United States
 

 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Association of Clinical Endocrinologists (AACE) and the Georgia Chapter of the American Association of Clinical Endocrinologists. AACE is accredited by the ACCME to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists designates this live activity for a maximum of 8 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclaimer

The information provided at this accredited activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Declaration of Disclosure and Conflicts of Interest

The American Association of Clinical Endocrinologists (AACE) remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of AACE to eliminate all situations of potential conflict of interest, but rather to enable those who are working with AACE to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the CME Subcommittee to ensure that such situations are properly evaluated and, if necessary, resolved. AACE educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all AACE accredited activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities.

Faculty Disclosures

 

 

Commercial Interest

 

 

What was Received

 

Rodolfo Galindo, MD

Program Committee

 

 

 

 

1. Abbott Diabetes Care

2. Novo Nordisk

3. Sanofi

 

 

1. Consulting Fees

2. Consulting Fees

3. Consulting Fees

 

Adriana Ioachimescu, MD, PhD, FACE

Program Committee

 

 

1. Chiasma

2. Novartis

3. Pfizer

4. Strongbridge

1. Research Grant

2. Research Grant

3. Consulting Fees

4. Research Grant

Barry Johns, MD, FACE

Program Committee

 

 

 

1. AstraZeneca

2. Boehringer Ingelheim

3. Lilly Diabetes

4. Novo Nordisk

1. Honorarium

2. Honorarium

3. Honorarium

4. Honorarium

Mark Molitch, MD

Faculty

 

 

1. Amgen

2. Bayer

3. Chiasma

4. Janssen

5. Merck

6. Novartis

7. NovoNordisk

8. Pfizer

9. Stonebridge

1. Spouse: Stockholder

2. Grant/Research Support

3. Grant/Research Support

4. Advisory Committee/Board Member

5. Consultant

6. Grant/Research Support

7. Grant/Research Support

8. Consultant

9. Grant/Research Support

Leigh Perreault, MD

Faculty

 

 

 

1. AstraZeneca Pharmaceuticals, LP

2. Boeringher-Ingelheim

3. Janssen

4. Merck

5. Novo Nordisk

6. Sanofi

1. Honorarium

2. Consultant, honorarium

3. Honorarium

4. Honorarium

5. Consultant/Advisory Board, Honorarium

6. Consultant/Advisory Board

Richard Pratley, MD

Faculty

 

 

1. AstraZeneca

2. Boeringher-Ingelheim

3. Eisai, Inc

4. GlaxoSmithKline

5. Janssen Pharmaceuticals, Inc.

6. Lexicon Pharmaceuticals

7. Ligand Pharmaceuticals, Inc.

8. Lilly

9. Merck

10. Sanofi US Services, Inc.

1. Consulting Fees

2. Consulting Fees

3. Consulting Fees

4. Consulting Fees

5. Consulting Fees

6. Grant/Research Support

7. Consulting Fees

8. Consulting Fees, Grant/Research Support

9. Consulting Fees, Grant/Research Support

10. Consulting Fees

Douglas Ross, MD

Faculty

 

1. Abbott India

2. Quest Diagnostics

3. Spectrix Therapeutics

4. Shire

 

1. Honorarium

2. Honorarium

3. Consulting Fees

4. Consultant/Advisory Board

All other faculty, planners and staff have disclosed no relevant financial relationships with commercial interests.

Available Credit

  • 8.00 AMA
  • 8.00 Attendance

Accreditation Period

Course opens: 
02/08/2019
Course expires: 
12/31/2019

Price

Cost:
$0.00
Please login or register to take this course.